DWA
GLMD icon

Dorsey Wright & Associates’s Galmed Pharmaceuticals GLMD Stock Holding History

Dorsey Wright & Associates’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-8
Closed -$10K – 301
2018
Q4 		$10K Buy
+8
New +$14K ﹤0.01% 263

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Dorsey Wright & Associates's GLMD Position: Q1 2019 in Review

Dorsey Wright & Associates sold out of Galmed Pharmaceuticals (GLMD) in Q1 2019, closing a stake of 8 shares — an estimated $10K sold.

Dorsey Wright & Associates first reported a position in GLMD in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 34 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

  • Dorsey Wright & Associates reported no remaining Galmed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 8 Galmed Pharmaceuticals shares in Q1 2019, an estimated $10K.
  • Dorsey Wright & Associates first reported a position in Galmed Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Galmed Pharmaceuticals position peaked at $10K in Q4 2018.
  • 34 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on Dorsey Wright & Associates's 13F filing for Q1 2019, filed 4 Apr 2019.